EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Status of long-acting-growth hormone preparations — 2015

Charlotte Høybye, Pinchas Cohen, Andrew R Hoffman, Richard Ross, Beverly M K Biller, Jens Sandahl Christiansen, Growth Hormone Research Society

Growth Hormone & IGF Research · 2015-10 · 25 (5) · 201-206

DOI: 10.1016/j.ghir.2015.07.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Growth Hormone & IGF Research, 2015-10. Verfasst von Charlotte Høybye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of endocrinology, metabolism and diabetology, Karolinska University Hospital, Stockholm, Sweden; Department of molecular medicine and surg…. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growth hormone (GH) treatment has been an established therapy for GH deficiency (GHD) in children and adults for more than three decades. Numerous studies have shown that GH treatment improves height, body composition, bone density, cardiovascular risk factors, physical fitness and quality of life and that the treatment has few side effects. Initially GH was given as intramuscular injections three times per week, but daily subcutaneous injections were shown to be more effective and less inconvenient and the daily administration has been used since its introduction in the 1980s. However, despite ongoing improvements in injection device design, daily subcutaneous injections remain inconvenient, painful and distressing for many patients, leading to noncompliance, reduced efficacy and increased health care costs. To address these issues a variety of long-acting formulations of GH have been developed. In this review we present the current status of long-acting GH preparations and discuss the specific issues related to their development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultChemistry, PharmaceuticalChildDelayed-Action PreparationsDrug Administration ScheduleGrowth DisordersHuman Growth HormoneHumansRecombinant Proteins

Stichwörter der Autor:innen

Growth hormoneGrowth hormone deficiencyGrowth hormone treatmentLong-acting growth hormone preparations

Substanzen

Delayed-Action PreparationsRecombinant ProteinsHuman Growth Hormone

Autor:innen und Institutionen

  • Department of endocrinology, metabolism and diabetology, Karolinska University Hospital, Stockholm, Sweden; Department of molecular medicine and surgery, Karolinska Institute, Stockholm, Sweden. Electronic address: char…
  • Leonard Davis School of Gerontology, University of Southern California, CA, USA.
  • Department of Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, USA.
  • Department of Human Metabolism, University of Sheffield, UK.
  • Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Endocrinology, MEA, Aarhus University Hospital, NBG, Aarhus, Denmark.

Zitieren

APA

Høybye, C., Cohen, P., Hoffman, A. R., Ross, R., Biller, B. M., Christiansen, J. S., & Growth Hormone Research Society (2015). Status of long-acting-growth hormone preparations — 2015. Growth Hormone & IGF Research, 25(5), 201-206. https://doi.org/10.1016/j.ghir.2015.07.004

Vancouver

Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM, Christiansen JS, et al. Status of long-acting-growth hormone preparations — 2015. Growth Hormone & IGF Research. 2015;25(5):201-206. doi:10.1016/j.ghir.2015.07.004

BibTeX
@article{Hybye2015,
  author = {Høybye, Charlotte and Cohen, Pinchas and Hoffman, Andrew R and Ross, Richard and Biller, Beverly M K and Christiansen, Jens Sandahl and Growth Hormone Research Society, Growth Hormone Research Society},
  title = {Status of long-acting-growth hormone preparations — 2015},
  journal = {Growth Hormone & IGF Research},
  year = {2015},
  volume = {25},
  number = {5},
  pages = {201--206},
  doi = {10.1016/j.ghir.2015.07.004}
}
Kostenlos starten →